FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ada Rephaeli

Research Profile

Chemicals & Drugs

Anatomy

Living Beings

Mouse

Physiology

Phenomena

Acetylation

Co-author Network

Publications

TOP 3
Robert A Forrest; Abraham Nudelman; Don R Phillips; Ada Rephaeli; Lonnie P Swift; Benny J Evison; Suzanne M Cutts
The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.
G Berkovitch-Luria; Abraham Nudelman; Ada Rephaeli; G Rozic; M Weitman; S Yakobovitch; zvi malik
A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells.
Robert A Forrest; Ken-Ichi Kimura; Abraham Nudelman; Don R Phillips; Ada Rephaeli; Lonnie P Swift; Suzanne M Cutts
Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ada Rephaeli (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Robert A Forrest; Abraham Nudelman; Don R Phillips; Ada Rephaeli; Lonnie P Swift; Benny J Evison; Suzanne M Cutts
The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.
Cancer chemotherapy and pharmacology 2013;71(3):809-16.
2012: G Berkovitch-Luria; Abraham Nudelman; Ada Rephaeli; G Rozic; M Weitman; S Yakobovitch; zvi malik
A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2012;47(1):206-14.
2012: Robert A Forrest; Ken-Ichi Kimura; Abraham Nudelman; Don R Phillips; Ada Rephaeli; Lonnie P Swift; Suzanne M Cutts
Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation.
Biochemical pharmacology 2012;83(12):1602-12.
2012: Gili Berkovitch-Luria; Abraham Nudelman; Ada Rephaeli; Michal Weitman; Zvi Malik
Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways.
Investigational new drugs 2012;30(3):1028-38.
2012: Nataly Tarasenko; Suzanne M Cutts; Aida Inbal; Gania Kessler-Icekson; Abraham Nudelman; Don R Phillips; Ada Rephaeli
Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor.
PloS one 2012;7(2):e31393.
2011: Tamar Feuerstein; Abraham Nudelman; Ada Rephaeli; Gili Berkovitch-Luria; Zvi Malik
Modulating ALA-PDT efficacy of mutlidrug resistant MCF-7 breast cancer cells using ALA prodrug.
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 2011;10(12):1926-33.
2010: Oula Mansour; Benny J Evison; Brad E Sleebs; Keith G Watson; Abraham Nudelman; Ada Rephaeli; Damian P Buck; J Grant Collins; Rebecca A Bilardi; Don R Phillips; Suzanne M Cutts
New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
Journal of medicinal chemistry 2010;53(19):6851-66.
2010: Michal Ugarenko; Abraham Nudelman; Ada Rephaeli; Ken-Ichi Kimura; Don R Phillips; Suzanne M Cutts
ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
Biochemical pharmacology 2010;79(3):339-49.
2010: Lilach Bareket; Ada Rephaeli; Gili Berkovitch; Abraham Nudelman; Judith Rishpon
Carbon nanotubes based electrochemical biosensor for detection of formaldehyde released from a cancer cell line treated with formaldehyde-releasing anticancer prodrugs.
Bioelectrochemistry (Amsterdam, Netherlands) 2010;77(2):94-9.
2009: Ada Rephaeli; Irit Gil-Ad; Ana Aharoni; Igor Tarasenko; Nataly Tarasenko; Yona Geffen; Efrat Halbfinger; Yotam Nisemblat; Abraham Weizman; Abraham Nudelman
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
Journal of medicinal chemistry 2009;52(9):3010-7.
2009: Michal Ugarenko; Chee-Kai Chan; Abraham Nudelman; Ada Rephaeli; Suzanne M Cutts; Don R Phillips
Development of pluronic micelle-encapsulated doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapy.
Oncology research 2009;17(7):283-99.
2009: Yona Geffen; Abraham Nudelman; Irit Gil-Ad; Ada Rephaeli; Mei Huang; Kinneret Savitsky; Leah Klapper; Ilan Winkler; Herbert Y Meltzer; Abraham Weizman
BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2009;19(1):1-13.
2008: Gili Berkovitch; Dvir Doron; Abraham Nudelman; zvi malik; Ada Rephaeli
Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation.
Journal of medicinal chemistry 2008;51(23):7356-69.
2008: Inesa Levovich; Abraham Nudelman; Gili Berkovitch; Lonnie P Swift; Suzanne M Cutts; Don R Phillips; Ada Rephaeli
Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species.
Cancer chemotherapy and pharmacology 2008;62(3):471-82.
2008: Rachela Popovtzer; Tova Neufeld; Aron Popovtzer; Ilia Rivkin; Raanan Margalit; Dikla Engel; Abraham Nudelman; Ada Rephaeli; Judith Rishpon; Yosi Shacham-Diamand
Electrochemical lab on a chip for high-throughput analysis of anticancer drugs efficiency.
Nanomedicine : nanotechnology, biology, and medicine 2008;4(2):121-6.
2008: Abraham Nudelman; Irit Gil-Ad; Nava Shpaisman; Igor Terasenko; Hanna Ron; Kinneret Savitsky; Yona Geffen; Abraham Weizman; Ada Rephaeli
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Journal of medicinal chemistry 2008;51(9):2858-62.
2008: Lonnie P Swift; Suzanne M Cutts; Abraham Nudelman; Inesa Levovich; Ada Rephaeli; Don R Phillips
The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Cancer chemotherapy and pharmacology 2008;61(5):739-49.
2008: Dikla Engel; Abraham Nudelman; Nataly Tarasenko; Inesa Levovich; Igor Makarovsky; Segev Sochotnikov; Igor Tarasenko; Ada Rephaeli
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Journal of medicinal chemistry 2008;51(2):314-23.
2008: Nataly Tarasenko; Abraham Nudelman; Igor Tarasenko; Michal Entin-Meer; Daphne Hass-Kogan; Aida Inbal; Ada Rephaeli
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex).
Clinical & experimental metastasis 2008;25(7):703-16.
2007: Diana Blank-Porat; Tal Gruss-Fischer; Nataly Tarasenko; zvi malik; Abraham Nudelman; Ada Rephaeli
The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties.
Cancer letters 2007;256(1):39-48.
2007: Michal Entin-Meer; Ada Rephaeli; Xiaodong Yang; Abraham Nudelman; Ayelet Nudelman; Daphne A Haas-Kogan
AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines.
Cancer letters 2007;253(2):205-14.
2007: Ada Rephaeli; S Waks-Yona; Abraham Nudelman; I Tarasenko; Nataly Tarasenko; Don R Phillips; Suzanne M Cutts; Gania Kessler-Icekson
Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity.
British journal of cancer 2007;96(11):1667-74.
2007: Suzanne M Cutts; Lonnie P Swift; Vinochani Pillay; Robert A Forrest; Abraham Nudelman; Ada Rephaeli; Don R Phillips
Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.
Molecular cancer therapeutics 2007;6(4):1450-9.
2007: Michal Entin-Meer; Xiaodong Yang; Scott R Vandenberg; Kathleen R Lamborn; Abraham Nudelman; Ada Rephaeli; Daphne A Haas-Kogan
In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.
Neuro-oncology 2007;9(2):82-8.
2006: Dikla Engel; Abraham Nudelman; Inesa Levovich; Tal Gruss-Fischer; Michal Entin-Meer; Don R Phillips; Suzanne M Cutts; Ada Rephaeli
Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines.
Journal of cancer research and clinical oncology 2006;132(10):673-83.
2006: Ada Rephaeli; Michal Entin-Meer; Dikla Angel; Nataly Tarasenko; Tal Gruss-Fischer; Irena Bruachman; Don R Phillips; Suzanne M Cutts; Daphne A Haas-Kogan; Abraham Nudelman
The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs.
Investigational new drugs 2006;24(5):383-92.
2006: Lonnie P Swift; Ada Rephaeli; Abraham Nudelman; Don R Phillips; Suzanne M Cutts
Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Cancer research 2006;66(9):4863-71.
2005: Michal Entin-Meer; Ada Rephaeli; Xiaodong Yang; Abraham Nudelman; Scott R Vandenberg; Daphne A Haas-Kogan
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.
Molecular cancer therapeutics 2005;4(12):1952-61.
2005: Suzanne M Cutts; Lonnie P Swift; Ada Rephaeli; Abraham Nudelman; Don R Phillips
Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.
Current medicinal chemistry. Anti-cancer agents 2005;5(5):431-47.
2005: Ada Rephaeli; Diana Blank-Porat; Nataly Tarasenko; Michal Entin-Meer; Inesa Levovich; Suzanne M Cutts; Don R Phillips; zvi malik; Abraham Nudelman
In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer.
International journal of cancer. Journal international du cancer 2005;116(2):226-35.
2005: Abraham Nudelman; Inesa Levovich; Suzanne M Cutts; Don R Phillips; Ada Rephaeli
The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
Journal of medicinal chemistry 2005;48(4):1042-54.
2005: Suzanne M Cutts; Abraham Nudelman; Ada Rephaeli; Don R Phillips
The power and potential of doxorubicin-DNA adducts.
IUBMB life 2005;57(2):73-81.
2005: Suzanne M Cutts; Abraham Nudelman; Vinochani Pillay; Damian M S Spencer; Inesa Levovich; Ada Rephaeli; Don R Phillips
Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.
Oncology research 2005;15(4):199-213.
2004: Belinda S Parker; Ada Rephaeli; Abraham Nudelman; Don R Phillips; Suzanne M Cutts
Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.
Oncology research 2004;14(6):279-90.
2003: Koren K Mann; Ada Rephaeli; April L Colosimo; Zuanel Diaz; Abraham Nudelman; Inesa Levovich; Yongkui Jing; Samuel Waxman; Wilson H Miller
A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis.
Molecular cancer research : MCR 2003;1(12):903-12.
2003: Suzanne M Cutts; Lonnie P Swift; Ada Rephaeli; Abraham Nudelman; Don R Phillips
Sequence specificity of adriamycin-DNA adducts in human tumor cells.
Molecular cancer therapeutics 2003;2(7):661-70.
2003: Belinda S Parker; Suzanne M Cutts; Abraham Nudelman; Ada Rephaeli; Don R Phillips; Saraswati Sukumar
Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.
Cancer biology & therapy 2003;2(3):259-63.
2003: Lonnie P Swift; Suzanne M Cutts; Ada Rephaeli; Abraham Nudelman; Don R Phillips
Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine.
Molecular cancer therapeutics 2003;2(2):189-98.
2002: Ayse Batova; Li-en Shao; Mitchell B Diccianni; Alice L Yu; Tetsuya Tanaka; Ada Rephaeli; Abraham Nudelman; John Yu
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
Blood 2002;100(9):3319-24.
2001: Suzanne M Cutts; Ada Rephaeli; Abraham Nudelman; I Hmelnitsky; Don R Phillips
Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
Cancer research 2001;61(22):8194-202.
2001: Abraham Nudelman; E Gnizi; Y Katz; R Azulai; Mirit Cohen-Ohana; Regina Zhuk; Sanford R Sampson; Leah Langzam; Eitan Fibach; Eugenia Prus; V Pugach; Ada Rephaeli
Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases.
European journal of medicinal chemistry 2001;36(1):63-74.
2000: Yael Zimra; Abraham Nudelman; Regina Zhuk; Esther Rabizadeh; Mati Shaklai; Adina Aviram; Ada Rephaeli
Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis.
Journal of cancer research and clinical oncology 2000;126(12):693-8.
2000: Abraham Nudelman; Ada Rephaeli
Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
Journal of medicinal chemistry 2000;43(15):2962-6.
1997: Adina Aviram; Ada Rephaeli; Mati Shaklai; Abraham Nudelman; Iris Ben-Dror; Lea Maron; Esther Rabizadeh
Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells.
Journal of cancer research and clinical oncology 1997;123(5):267-71.
1997: Yael Zimra; L Wasserman; Lea Maron; Mati Shaklai; Abraham Nudelman; Ada Rephaeli
Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells.
Journal of cancer research and clinical oncology 1997;123(3):152-60.
1996: Esther Rabizadeh; Mati Shaklai; L Eisenbach; Abraham Nudelman; Ada Rephaeli
Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9).
Israel journal of medical sciences 1996;32(12):1186-91.
1994: A Aviram; Y Zimrah; Mati Shaklai; Abraham Nudelman; Ada Rephaeli
Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line.
International journal of cancer. Journal international du cancer 1994;56(6):906-9.
1993: Esther Rabizadeh; Mati Shaklai; Abraham Nudelman; L Eisenbach; Ada Rephaeli
Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug.
FEBS letters 1993;328(3):225-9.
1992: Abraham Nudelman; M Ruse; A Aviram; Esther Rabizadeh; Mati Shaklai; Y Zimrah; Ada Rephaeli
Novel anticancer prodrugs of butyric acid. 2.
Journal of medicinal chemistry 1992;35(4):687-94.
1991: Ada Rephaeli; Esther Rabizadeh; A Aviram; Mati Shaklai; M Ruse; Abraham Nudelman
Derivatives of butyric acid as potential anti-neoplastic agents.
International journal of cancer. Journal international du cancer 1991;49(1):66-72.
1990: Ada Rephaeli; A Aviram; Esther Rabizadeh; T Englender; Mati Shaklai
The role of calcium in differentiation of leukemic cell lines.
Cancer biochemistry biophysics 1990;11(2):119-25.
1990: Ada Rephaeli; A Aviram; Esther Rabizadeh; Mati Shaklai
Proliferation-associated changes of Ca2+ transport in myeloid leukemic cell lines.
Journal of cellular physiology 1990;143(1):154-9.
1990: A Aviram; Ada Rephaeli; Mati Shaklai
The role of increased calcium influx rate in receptor mediated function of differentiating HL-60 cells.
Cell calcium 1990;11(4):269-74.
1988: Ada Rephaeli; A Aviram; T Englender; Mati Shaklai
Differentiation-associated changes of cation-transport activities in myeloid leukemic cell lines.
FEBS letters 1988;236(2):401-5.